

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022



## MDTM Research Questionnaire

*This questionnaire will be hosted on Online Surveys. Table columns marked \* will not be included in the survey and are included here for review purposes only. The order and formatting of questions may change.*

\*\*\*

**Thank you for agreeing to take part in this survey as part of the study:**

**Changing from face-to-face to virtual meetings during the COVID-19 pandemic: exploring the impact on cancer multi-disciplinary team (MDT) meetings.**

Question #	Question	Response options	Who asked*	Construct being measured*
<b>SECTION 1: About you and basic information</b>				
1	What is your email address?	Freetext	ALL	Characteristics
2	In which Cancer Alliance do you work?	Drop down list of all Cancer Alliances in England	ALL	Characteristics
3	What is your gender?	<ul style="list-style-type: none"> <li><input type="radio"/> Female</li> <li><input type="radio"/> Male</li> <li><input type="radio"/> Other (please state)</li> <li><input type="radio"/> Prefer not to say</li> </ul>	ALL	Characteristics
4	What is your age?	<ul style="list-style-type: none"> <li><input type="radio"/> 18-30</li> <li><input type="radio"/> 31-45</li> <li><input type="radio"/> 46-60</li> <li><input type="radio"/> 61+</li> <li><input type="radio"/> Prefer not to say</li> </ul>	ALL	Characteristics
5	What is your ethnicity?	<ul style="list-style-type: none"> <li><input type="radio"/> Select from 16 ONS categories</li> <li><input type="radio"/> Prefer not to say</li> </ul>	ALL	Characteristics

Page 1 of 9

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
6	Which type(s) of cancer does your MDT manage? <sup>1</sup> (Select all types managed by your MDT)	Drop down list of all cancer types (option to select more than one)	ALL	Characteristics
7	Do you currently act as an MDT lead?	<input type="radio"/> Yes <input type="radio"/> No	ALL	Characteristics
8	What is your role in cancer MDT meetings? <sup>1</sup> (Select all that apply)	<input type="radio"/> Administrator <input type="radio"/> Clinical Oncologist <input type="radio"/> Endoscopist <input type="radio"/> Interventional Radiologist <input type="radio"/> Manager <input type="radio"/> MDT lead <input type="radio"/> MDT co-ordinator <input type="radio"/> Medical Secretary <input type="radio"/> Medical Oncologist <input type="radio"/> Oncology CNS <input type="radio"/> Nuclear Radiologist <input type="radio"/> Nurse Practitioner <input type="radio"/> Pathologist <input type="radio"/> Patient representative <input type="radio"/> Radiologist <input type="radio"/> STT CNS <input type="radio"/> Surgeon <input type="radio"/> Other – specify	ALL	Characteristics
9a	<p>In this study, we are using the following definitions:</p> <ul style="list-style-type: none"> <li>• <b>Virtual</b> MDT meetings are meetings where all members attend the meeting virtually (i.e. no face-to-face meeting).</li> <li>• <b>Face-to-face</b> MDT meetings are meetings where all members attend the meeting face-to-face.</li> <li>• <b>Hybrid</b> MDT meetings are meetings conducted with some members attending face-to-face and others joining virtually.</li> </ul> <p>Using these definitions, what was the format of the majority of your cancer MDT meetings <b>before the pandemic</b>?<sup>1</sup></p>	<input type="radio"/> Virtual <input type="radio"/> Face-to-face <input type="radio"/> Hybrid (a combined virtual and face-to-face meeting)	ALL	Characteristics

Page 2 of 9

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
9b	Using these definitions, what is the format of the majority of your cancer MDT meetings <b>currently</b> ? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Virtual</li> <li>○ Face-to-face</li> <li>○ Hybrid (a combined virtual and face-to-face meeting)</li> </ul>	ALL	Characteristics
10	Overall, to what extent do you feel virtual cancer MDT meetings result in the optimum treatment management decisions being made for each patient, when compared to face-to-face meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Much better treatment management decisions are made in virtual cancer MDT meetings</li> <li>○ Slightly better treatment management decisions are made in virtual cancer MDT meetings</li> <li>○ No difference</li> <li>○ Slightly better treatment management decisions are made in face-to-face cancer meetings</li> <li>○ Much better treatment management decisions are made in face-to-face meetings</li> </ul>	ALL	Characteristics
<b>SECTION 2: The Team</b>				
11	In your experience, on average, how well-attended are virtual cancer MDT meetings when compared to face-to-face cancer MDT meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Attendance is higher in virtual cancer MDT meetings</li> <li>○ Attendance is the same</li> <li>○ Attendance is lower in virtual cancer MDT meetings</li> <li>○ Not sure</li> </ul>	ALL	The Team – attendance
12	How likely is it that you would attend the whole of a virtual cancer MDT meeting (not just relevant parts), when compared with face-to-face cancer MDT meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ More likely to attend the whole meeting if virtual</li> <li>○ Equally likely</li> <li>○ More likely to attend whole meeting if face-to-face</li> </ul>	ALL	The Team – attendance

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
13	Thinking about MDT member attendance at each cancer MDT meeting, how well-represented is your clinical speciality during virtual meetings, when compared with face-to-face meetings? <sup>5</sup>	<ul style="list-style-type: none"> <li>○ Better representation of my specialty in virtual meetings</li> <li>○ About the same</li> <li>○ Better representation of my specialty in face-to-face meetings</li> </ul>	ALL from clinical specialties	The Team – disciplinary composition
<b>SECTION 3: Organisation and logistics</b>				
14a	Is the amount of time you <u>need to spend preparing</u> for each cancer MDT meeting different for virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>2</sup>	<ul style="list-style-type: none"> <li>○ Yes, I need less time to prepare for a virtual meeting</li> <li>○ No, I need the same time</li> <li>○ Yes, I need more time to prepare for a virtual meeting</li> </ul>	LEAD	Organisation and logistics – preparation
14b	Is the amount of time <u>you have available</u> for that preparation for each cancer MDT meeting different for virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>2</sup>	<ul style="list-style-type: none"> <li>○ Yes, I have less time available to prepare for virtual meetings</li> <li>○ No, I have the same time</li> <li>○ Yes, I have more time available to prepare for virtual meetings</li> </ul>	LEAD	Organisation and logistics – preparation
15	How often does the meeting over-run to complete the agenda during virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Virtual meetings over-run more often</li> <li>○ Equally often</li> <li>○ Face-to-face meetings over-run more often</li> </ul>	ALL	Organisation and logistics – timing and streamlining
16	How often is the meeting agenda organised to prioritise discussion of more complex cases during virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ More often have a prioritised agenda during virtual cancer MDT meetings</li> <li>○ Equally likely</li> <li>○ More often have a prioritised agenda during face-to-face meetings</li> </ul>	ALL	Organisation and logistics – timing and streamlining
17	How much time do you have to discuss each patient during virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>5</sup>	<ul style="list-style-type: none"> <li>○ More time per patient</li> <li>○ About the same time per patient</li> <li>○ Less time per patient</li> </ul>	ALL	Organisation and logistics – timing and streamlining
18	In how much depth are you able to discuss each patient during virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>3</sup>	<ul style="list-style-type: none"> <li>○ More depth of discussion per patient</li> </ul>	ALL	Organisation and logistics – timing and streamlining

Page 4 of 9

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
		<ul style="list-style-type: none"> <li>○ About the same depth of discussion per patient</li> <li>○ Less depth of discussion per patient</li> </ul>		
<b>SECTION 4: Meeting infrastructure</b>				
<b>19a</b>	How often have problems with technology negatively affected your participation in virtual cancer MDT meetings? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Never</li> <li>○ Rarely</li> <li>○ Sometimes</li> <li>○ Often</li> <li>○ Always</li> </ul>	ALL	Infrastructure – resource and equipment
<b>19b</b>	What problems with technology do you routinely experience in virtual cancer MDT meetings? (Select all that apply) <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Logging on</li> <li>○ Wifi stability</li> <li>○ Audio quality</li> <li>○ Visual quality</li> <li>○ Other – please specify</li> </ul>	ALL	Infrastructure – resource and equipment
<b>20</b>	When attending virtual or hybrid cancer MDT meetings, how often does the organisation you work for provide <u>access to a room or space</u> with appropriate privacy to join a cancer MDT meeting virtually? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Never</li> <li>○ Rarely</li> <li>○ Sometimes</li> <li>○ Often</li> <li>○ Always</li> </ul>	ALL	Infrastructure – resource and equipment
<b>21</b>	When attending virtual or hybrid cancer MDT meetings, how often does the organisation you work for provide <u>access to appropriate equipment</u> to join a cancer MDT meeting virtually? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Never</li> <li>○ Rarely</li> <li>○ Sometimes</li> <li>○ Often</li> <li>○ Always</li> </ul>	ALL	Infrastructure – resource and equipment
<b>SECTION 5: Governance</b>				
<b>22</b>	How confident do you feel chairing a cancer MDT meeting virtually, when compared to face-to-face? <sup>4</sup>	<ul style="list-style-type: none"> <li>○ More confident</li> <li>○ Same confidence</li> <li>○ Less confident</li> </ul>	LEAD	Governance – chairing
<b>23</b>	Have you had any prior training in chairing cancer MDT meetings, either face-to-face or virtually? <sup>4</sup>	<ul style="list-style-type: none"> <li>○ Yes, I have had training in chairing of virtual MDT meetings only</li> <li>○ Yes, I have had training in chairing of face-to-face MDT meetings only</li> <li>○ Yes, I have had training in chairing for BOTH virtual and face-to-face MDT meetings</li> </ul>	LEAD	Governance – chairing

Page 5 of 9

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
		<ul style="list-style-type: none"> <li>○ No, I have never had training in chairing MDT meetings</li> </ul>		
24	Does the MDT record/log any operational problems and serious incidents (e.g. persistent failure of IT, failure of transfer of information/images in time, failure to act on critical results etc.)? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Yes, always</li> <li>○ Yes, sometimes</li> <li>○ No, not usually</li> <li>○ No, never</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
25	Is your virtual cancer MDT meeting performance audited through an annual MDT review meeting? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Yes</li> <li>○ No</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
26	Are patient outcomes following virtual cancer MDT meetings audited through an annual MDT review meeting? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Yes</li> <li>○ No</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
27	Are there any other processes in place to monitor and evaluate your virtual cancer MDT meeting performance in addition to, or instead of, an annual MDT review meeting? <sup>1</sup>	<ul style="list-style-type: none"> <li>○ Yes</li> <li>○ No</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
27b	(If yes to previous question) If yes, what monitoring and evaluation processes are in place for your virtual cancer MDT meeting performance? <sup>1</sup>	Freetext	LEAD	Governance – audit
28	Do you have any suggestions for how virtual cancer MDT performance could be more effectively monitored or audited to inform quality improvement? <sup>1</sup>	Freetext	LEAD	Governance – audit
29	Following virtual cancer MDT meetings, are all MDT decisions and outcomes checked by a clinical member of the team before being finalised? <sup>2</sup>	<ul style="list-style-type: none"> <li>○ Yes, always</li> <li>○ Yes, sometimes</li> <li>○ No, not usually</li> <li>○ No, never</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
30	Do you feel there is adequate ‘sign-off’ and follow-up of MDT outcomes after virtual cancer MDT meetings, to ensure actions are completed? <sup>2</sup>	<ul style="list-style-type: none"> <li>○ Yes, always</li> <li>○ Yes, sometimes</li> <li>○ No, not usually</li> <li>○ No, never</li> <li>○ Unsure</li> </ul>	LEAD	Governance – audit
<b>SECTION 6: Decision-making</b>				

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
31	How often are you able to access all relevant patient details (e.g., clinical information, scan images) during virtual cancer MDT meetings? <sup>3</sup>	<input type="radio"/> Never <input type="radio"/> Rarely <input type="radio"/> Sometimes <input type="radio"/> Often <input type="radio"/> Always	ALL	Decision-making – orientation
32	How clearly are you able to view relevant patient information (e.g., clinical information, scan images, pathology specimens) during virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>3</sup>	<input type="radio"/> More clearly <input type="radio"/> About the same <input type="radio"/> Less clearly	ALL	Decision-making – orientation
33	How able are you to concentrate throughout virtual cancer MDT meetings, when compared with face-to-face cancer MDT meetings? <sup>1</sup>	<input type="radio"/> My concentration is better <input type="radio"/> My concentration is the same <input type="radio"/> My concentration is worse	ALL	Decision-making – orientation
34	How well are you able to interact with other specialists during virtual cancer MDT meetings, when compared with face-to-face MDT meetings? <sup>3</sup>	<input type="radio"/> Better <input type="radio"/> About the same <input type="radio"/> Not as well	ALL	Decision-making – discussion
35	How comfortable do you feel contributing to discussions about patients during virtual cancer MDT meetings, when compared to face-to-face meetings? <sup>1</sup>	<input type="radio"/> More comfortable <input type="radio"/> About the same <input type="radio"/> Less comfortable	ALL	Decision-making – discussion
36	How often do you contribute to the decisions made about patients during virtual cancer MDT meetings, when compared with face-to-face meetings? <sup>5</sup>	<input type="radio"/> More often <input type="radio"/> About the same <input type="radio"/> Less often	ALL	Decision-making – decision
37a	Does the process by which a final decision is agreed upon in a virtual MDT meeting depend on how complex the case discussion is? <sup>1</sup>	<input type="radio"/> Yes <input type="radio"/> To some extent <input type="radio"/> No	ALL	Decision-making – case-complexity
37b	(If answered 'Yes' or 'To some extent' to previous question) How are final decisions agreed for more complex cases compared to simpler cases in virtual MDT meetings? <sup>1</sup>	Freetext	ALL	Decision-making – case-complexity
38	How does complexity in each of the following domains affect the amount of time spent discussing a case during virtual cancer MDT meetings, when compared to face-to-face-meetings? <sup>1,6</sup>	<i>See below:</i>	ALL	Decision-making – case-complexity
38a	Pathology of the tumour	<input type="radio"/> More time spent in virtual meetings <input type="radio"/> About the same	ALL	Decision-making – case-complexity
38b	Psychosocial characteristics of the patient	<input type="radio"/> More time spent in face-to-face meetings	ALL	Decision-making – case-complexity

Page 7 of 9

IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

Question #	Question	Response options	Who asked*	Construct being measured*
38c	Physical characteristics of the patient		ALL	Decision-making – case-complexity
38d	Treatment factors (e.g., uncertainty, toxicity, lack of pathway)		ALL	Decision-making – case-complexity
39a	Are there any differences in how services for the patient are co-ordinated following a virtual MDT meeting compared to a face-to-face MDT meeting? <sup>1</sup>	<input type="radio"/> Yes <input type="radio"/> No	ALL	Decision-making – implementation
39b	(If answered yes to previous question) What differences are there? <sup>1</sup>	Freetext	ALL	Decision-making – implementation
<b>SECTION 7: Advantages, disadvantages and recommendations</b>				
40	Can you suggest three improvements that could be made to virtual cancer MDT meetings? <sup>1</sup>	Freetext	ALL	Advantages, disadvantages and recommendations
41	If you could choose between virtual MDT meetings, hybrid MDT meetings or face-to-face MDT meetings, which would you choose? <sup>1</sup>	<input type="radio"/> Face-to-face only <input type="radio"/> Hybrid meetings <input type="radio"/> Virtual only	ALL	
42	What are the three most important advantages of virtual cancer MDT meetings compared to face-to-face meetings? <sup>1</sup>	Freetext	ALL	
43	What are the three most important disadvantages of virtual cancer MDT meetings compared to face-to-face meetings? <sup>1</sup>	Freetext	ALL	
44	What, if any, are the advantages of hybrid cancer MDT meetings compared to virtual and face-to-face meetings? <sup>1</sup>	Freetext	ALL	
5	What, if any, are the disadvantages of hybrid cancer MDT meetings compared to virtual and face-to-face meetings? <sup>1</sup>	Freetext	ALL	
<b>Results</b>				
46	Would you like to receive an email with the results of the survey and/or any resulting publications? <sup>1</sup>	<input type="radio"/> Yes <input type="radio"/> No	ALL	Results
47	Would you be willing to be contacted about taking part in an interview with a researcher (by telephone or MS Teams) to explore your experiences of virtual and hybrid MDT meetings?	<input type="radio"/> Yes <input type="radio"/> No	ALL	Results

**You've finished!**

*Thank you very much for taking the time and thought to contribute to this survey.*



IRAS ID: 307410

Appendix 2b. Cancer MDTM Research – Validated Questionnaire - V0.4 29 June 2022

**Question sources:**

- 1 New/original
- 2 Wording adapted from: Mughal M, Goodman J. MDT Improvement Report. 2017.
- 3 Wording adapted from: Rajasekaran RB, Whitwell D, Cosker TDA, Gibbons CLMH, Carr A. Will virtual multidisciplinary team meetings become the norm for musculoskeletal oncology care following the COVID-19 pandemic? - experience from a tertiary sarcoma centre. *BMC Musculoskelet Disord.* 2021 Jan 5;22(1):18. doi: 10.1186/s12891-020-03925-8. PMID: 33402136; PMCID: PMC7784619
- 4 Unknown
- 5 New/original but based on themes of framework and observational tools used in: Soukup T, Lamb BW, Morbi A, Shah NJ, Bali A, Asher V, et al. A multicentre cross-sectional observational study of cancer multidisciplinary teams: Analysis of team decision making. *Cancer Med.* 2020;9(19):7083–99.
- 6 Based on constructs in the MeDiC tool: Soukup T, Morbi A, Lamb BW, Gandamihardja TAK, Hogben K, Noyes K, Skolarus TA, Darzi A, Sevdalis N, Green JSA. A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool. *Cancer Med.* 2020 Jul;9(14):5143-5154. doi: 10.1002/cam4.3026. Epub 2020 May 31. PMID: 32476281; PMCID: PMC7367630.